Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · BIODESIX INC (BDSX)

Biodesix Q3 revenue rises 10% to $24.0 million; full-year 2026 revenue guidance revised

Mixed Impact 4 of 5 earnings Written later

Biodesix reported third-quarter 2026 revenue of $24.0 million, up 10% year over year, and a net loss of $8.0 million, narrowed 8% from a year earlier. The company revised its full-year 2026 revenue guidance to $101 million to $103 million, and CEO Scott Hutton said growth was below the company's expectations, citing sales team, seasonality and development services timing issues.

Key points

  • Total revenue $24.0 million in Q3 2026, up 10%; Diagnostic Testing revenue $23.0 million, up 16%
  • Test volumes rose 24% to 19,400; gross margin was 81%, flat year over year
  • Net loss $8.0 million vs. $8.7 million a year earlier; Adjusted EBITDA loss $3.9 million vs. $4.6 million
  • Full-year 2026 revenue guidance revised to $101 million to $103 million

The filing

CompanyBIODESIX INC (BDSX)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:03 PM ET
Accession number0001193125-26-449738

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.